ASPARTAME

Comments:

Overall, JECFA concluded that there was no convincing evidence from experimental animal or human data that aspartame has adverse effects after ingestion. This conclusion is underpinned by the information that aspartame is fully hydrolysed in the gastrointestinal tract into metabolites that are identical to those absorbed after consumption of common foods, and that no aspartame enters the systemic circulation. JECFA concluded that the data evaluated at the present meeting indicated no reason to change the previously established ADI of 0–40 mg/kg bw for aspartame. JECFA therefore reaffirmed the ADI of 0–40 mg/kg bw for aspartame at the present meeting.

Intake:

JECFA determined that dietary exposure estimates to aspartame at the mean of up to 10 mg/kg bw per day for children and 5 mg/kg bw per day for adults, and for high dietary exposures up to 20 mg/kg bw per day for children and 12 mg/kg bw per day for adults, were appropriate for the present assessment. JECFA noted that these dietary exposure estimates do not exceed the ADI. JECFA therefore concluded that dietary exposure to aspartame does not pose a health concern.

Meeting:

96

Specs Code:

R

Report: 

Specification: 

ADI:

0-40 mg/kg bw

Comments:

Considered for specifications only

Meeting:

82

Specs Code:

R,T

Report: 

Specification: 

ADI:

0-40 mg/kg bw

Comments:

Aspartame has been considered by JECFA at its 19th, 20th, 21st, 23rd and 24th meeting. The 24th JECFA meeting allocated and ADI for aspartame of 0-40 mg/kg bw. At its 25th meeting JECFA considered the result of an additional long-term study on aspartame and the diketopiperazine impurity in rats and further biochemical studies of aspartame in humans. The ADI allocated at the 24th JECFA meeting was confirmed.

Meeting:

25

Specs Code:

R

Report: 

Tox Monograph: 

Specification: 

Previous Years: